OUR AREAS OF INTEREST

Atherosclerosis and
Cardiovascular Diseases

  • Lipids / Metabolic Syndrome

    Areas of Interest:

    • Lipid-lowering therapies
      • Agents with effect on LDL / Apo B
      • Agents with additional effect on glucose, triglycerides, blood pressure, body weight, and / or HDL
    • HDL-raising therapies
      • Acute HDL therapy for high-risk patients (eg, HDL infusion)
      • Oral compounds, with known mechanism of action, that increase HDL-C or Apo-A1 levels and have additional evidence to increase confidence that such mechanism will reduce cardiovascular risk

    Technology / Methods:

    • Discovery
      • Collaborations for identifying, validating, and developing novel lipid / metabolic and / or other emerging targets with pre-clinical or human genetic validation and high confidence for reducing CV risk
      • Animal models with strong evidence of translational value
    • Biomarkers
      • Methods, biomarkers, or platforms to assess antiatherogenic properties of HDL or other lipoproteins
      • Translational biomarkers of atherothrombosis
      • Biomarkers of patient subtypes
      • Acute methods to assess cholesterol transport in humans (especially reverse cholesterol transport), including imaging and kinetic models
      • Novel imaging technologies with evidence of translational value

    Academic Collaborations:

    • Research collaborations in the above areas on novel targets and their involvement in disease processes
    • Research collaborations on novel targets in other areas with strong human genetic and / or pharmacological validation

    Not Interested In:

    • Fibrates or other PPAR-alpha agonists

  • Specialty Hypertension / Cardiovascular

    Specialty hypertension includes hypertensive segments with high unmet medical need such as systolic HTN, resistant HTN, HTN associated with obesity and diabetes, HTN with associated heart failure, HTN with chronic kidney disease, and pulmonary HTN

    Areas of Interest:

    • Diuretics
    • Long-acting vasorelaxants
    • Agents that inhibit aldosterone synthesis and / or action
    • Agents that lower blood pressure and have pleiotropic benefits on end-organ protection (especially cardiac, renal, and vascular)
    • Antihypertensive agents with additional benefits on other components of metabolic syndrome and other cardiovascular risk factors
    • Agents for pulmonary hypertension
    • Heart failure agents that affect structural cardiac remodeling and have antihypertensive effects

    Technology / Methods:

    • Discovery
      • Animal models of hypertension and end-organ damage (cardiac, pulmonary vascular, renal) with strong evidence of translational value
    • Biomarkers
      • Technologies for measuring vascular dynamics (eg, flow, shear stress, vascular compliance) and intravascular pressure beyond tonometry
      • Markers for renal sequelae of HTN (eg, renal perfusion and renal injury)
      • Platform technologies that enable personalized medicine for HTN

    Academic Collaborations:

    • Research collaborations in the above areas on novel targets and their involvement in disease processes
    • Research collaborations on novel targets in other areas with strong human genetic and / or pharmacological validation

    Not Interested In:

    • ACE inhibitors, ARBs, CCBs, beta-blockers, adrenergic agents
    • Nutraceuticals

  • Thrombosis and Other Areas (Outside Lipids and Hypertension)

    Areas of Interest:

    • Novel anti-coagulants that offer potential for improved efficacy and / or reduced bleeding risk as compared to warfarin, DTIs, Factor Xa inhibitors
    • Novel anti-platelet agents with improved efficacy / safety over standard-of-care
    • Direct vessel wall-active agents with strong genetic validation and / or human pharmacological POC

    Technology / Methods:

    • Preclinical models, clinical models, and / or biomarkers that can be used to differentiate anti-coagulant mechanisms based on efficacy and / or bleeding risk
    • Preclinical models, clinical models, and / or biomarkers that can be used to differentiate anti-platelet mechanisms based on efficacy and / or bleeding risk

    Academic Collaborations:

    • Research collaborations in the above areas on novel targets and their involvement in disease processes
    • Research collaborations on novel targets in other areas with strong human genetic and / or pharmacological validation

    Not Interested In:

    • Agents without clinical POC for:
      • Acute treatments for MI
      • Post-MI therapeutics for myocardial preservation or perfusion-reperfusion injury
    • Treatment of restenosis
    • Heparins

Areas of Interest

Click on the icons below for more information about your areas of interest.

Research & Enabling Technologies Atherosclerosis and Cardiovascular Diseases Biologics Respiratory and Immunology Diabetes and Endocrinology Infectious Diseases Neurosciences and Ophthalmology Oncology Therapeutics Vaccines

Have a Discovery?

If you think something you discovered might be of interest to Merck, contact one of our scientific scouts.

Learn more about us

TRUSTe - Click to Verify   This Web This Web Accessibility icon serves as a link to download eSSENTIAL Accessibility assistive technology software for individuals with physical disabilities. It is being featured as part of a Disability Community Involvement initiative that reflects our commitment to Diversity, Inclusion,Corporate Citizenship and Social Responsibility.